Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melissa Harrison

Nurse Practitioner Northport, AL Nurse Practitioner

NPI 1811971468 CMS profile 10962616

4280 Watermelon Rd Ste 112, Northport, AL 35473

Open in the dashboard

General payments

$3,648

215 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Harrison of Northport, AL is reported in the CMS Open Payments database as having received $3,648 across 215 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,131 58
2024 General $235 11
2023 General $56 3
2022 General $441 25
2021 General $1,785 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Harrison
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Melissa Harrison were reported at $1,131. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Melissa Harrison Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,785 $135 $40–$426 $132
2022 $441 $152 $48–$470 $149
2023 $56 $166 $54–$529 $160
2024 $235 $173 $55–$556 $164
2025 $1,131 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $781 47 payments
  2. Amgen Inc. $561 41 payments
  3. UCB, Inc. $405 24 payments
  4. Janssen Biotech, Inc. $370 23 payments
  5. Mallinckrodt Hospital Products Inc. $322 10 payments
  6. Pfizer Inc. $269 18 payments
  7. Novartis Pharmaceuticals Corporation $201 11 payments
  8. E.R. Squibb & Sons, L.L.C. $99 6 payments
  9. ANI Pharmaceuticals, Inc. $93 3 payments
  10. GlaxoSmithKline, LLC. $75 5 payments
  11. Other $473 27 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,634 214 payments
  2. Education $14 1 payment
Products named General payments · program years 2021–2025
  1. RINVOQ $658 41 payments
  2. TREMFYA $325 19 payments
  3. ACTHAR $322 10 payments
  4. XELJANZ $244 16 payments
  5. SIMPONI ARIA $227 15 payments
  6. Enbrel $220 16 payments
  7. Cimzia $212 15 payments
  8. COSENTYX $201 11 payments
  9. Bimzelx $194 9 payments
  10. Otezla $139 9 payments
  11. Other $1,552 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

215 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record